Want to see TSE:ADK full AI Analyst Report?
ADK Stock Chart & Stats
C$0.36
C$0.03(9.38%)
At close: 4:00 PM EST
C$0.36
C$0.03(9.38%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.42
Previous CloseN/A
Volume270.50K
Average Volume (3M)342.67K
Market Cap
C$32.51M
Enterprise ValueC$23.50M
Total Cash (Recent Filing)C$1.93M
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-based CARA Retinal Screening PlatformDiagnos’s CARA is a software/AI screening platform, a scalable, non-inventory business model that can be deployed across clinics and screening programs. Durable software delivery supports per-test or subscription revenue, enabling recurring revenue as screening volumes grow.
Focused Clinical Use Case (retinal Disease Screening)A clear, narrowly defined clinical use case—retinal disease screening—aligns the product with established healthcare workflows. That focus supports targeted product development, easier provider adoption, and repeatable integration into screening programs over multi-year horizons.
Lean Operating FootprintA small employee base implies lower fixed overhead and operational flexibility, which can extend runway and enable incremental scaling of a software platform without proportionate increases in staff costs. This lean structure aids durability while commercialization grows.
Bears Say
Sharp Revenue ContractionRevenue erosion of this magnitude signals weakening commercial traction and raises doubts about product-market fit and customer retention. Shrinking scale undermines leverage on fixed costs, reduces ability to invest in sales/clinical validation, and constrains long-term growth visibility.
Sustained Negative Operating Cash FlowPersistent, large negative operating cash flows force reliance on external financing and increase dilution or refinancing risk. Continued cash burn depletes runway, limits investment in commercialization and regulatory work, and threatens continuity absent durable funding sources.
High Leverage And Fragile Balance SheetDebt at roughly twice equity with a history of negative equity tightens financial flexibility and elevates refinancing risk. Combined with ongoing losses and cash burn, leverage constrains the company’s ability to fund growth initiatives or absorb adverse clinical/commercial setbacks over the coming months.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.17 and its highest was C$0.41 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$32.51M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Jun 11, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diagnos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.46%
12-Months-Change
Fundamentals
Return on Equity
9999.00%
Trailing 12-Months
Asset Growth
-34.26%
Trailing 12-Months
Company Description
Diagnos
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations focuses on healthcare, where it provides Computer Assisted Retina Analysis (CARA). This advanced web-based platform is designed to support medical professionals in the early detection of diabetic retinopathy. It also empowers eye care specialists by enabling clear visualization of both standard retinal features and any pathological changes. Beyond its healthcare offerings, DIAGNOS Inc. extends its expertise through consulting services, specializing in the fields of data analytics and artificial intelligence (AI). Established in 1998, the company maintains its corporate headquarters in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---